Sirnaomics
Gaithersburg, US · Delaware corporation · 1 known investors
Sirnaomics is an RNA therapeutics company developing RNA interference (RNAi) drugs using its proprietary PNP (Peptide Nanoparticle) delivery platform for extra-hepatic delivery and its GalAHead technology for controlling therapeutic duration. Its pipeline spans oncology, regenerative and aesthetic medicine, and cardiovascular and metabolic diseases.
Founders & leadership
Y(
Yang (Patrick) Lu, PhDFounder
GJ
George JiinChief Business Administrator2023–2025
MM
Michael MolyneauxExecutive
Board
XD
Xiaochang DaiBoard director
PL
Ping LauBoard director
MG
Mike GhiasBoard director
Investors · 1
Also in the syndicate · 1
Rotating Boulder Fundlead
Reported raises · per SEC filings
Form D private placements$162M disclosed across 5 rounds · 2016–2020
▶$15MraisedDec 2020 · 3 investors · BiotechnologyRule 506(b)
▶$15MraisedDec 2020 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael V Molyneaux, MD, MBAExecutive Officer, Director
- Mike M Ghias, MBADirector
- Yang (Patrick) Lu, PhDExecutive Officer, Director
- Rong Lu, MBADirector
- Da LiuDirector
- Xiaochang Dai, PhDDirector
- Huang Mingcong (Cooper)Director
- Offering amount
- $15M
- Amount sold
- $15M
- Minimum investment
- $1M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$89MraisedDec 2020 · 10 investors · BiotechnologyRule 506(b)
▶$89MraisedDec 2020 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rong Lu, MBADirector
- Mongcong (Cooper) HuangDirector
- Xiaochang Dai, PhDDirector
- Michael V Molyneaux, MD, MBAExecutive Officer, Director
- Mike M Ghias, MBADirector
- Yang (Patrick) Lu, PhDExecutive Officer, Director
- Da LiuDirector
- Offering amount
- $89M
- Amount sold
- $89M
- Minimum investment
- $1M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$23MraisedJul 2019 · 7 investors · BiotechnologyRule 506(b)
▶$23MraisedJul 2019 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrick Y Lu, PhDExecutive Officer, Director
- Mike Ghias, MBADirector
- Rong Lu, MBADirector
- Xiaochang Dai, PhDDirector
- Ping Lau, MBADirector
- Michael Molyneaux, MD, MBAExecutive Officer, Director
- Offering amount
- $23M
- Amount sold
- $23M
- Minimum investment
- $1M
- First sale
- Mar 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25MraisedJul 2019 · 6 investors · BiotechnologyRule 506(b)
▶$25MraisedJul 2019 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrick Y Lu, PhDExecutive Officer, Director
- Mike Ghias, MBADirector
- Xiaochang Dai, PhDDirector
- Ping Lau, MBADirector
- Rong Lu, MBADirector
- Michael Molyneaux, MD, MBAExecutive Officer, Director
- Offering amount
- $25M
- Amount sold
- $25M
- Minimum investment
- $118K
- Finders' fees
- $100K
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedApr 2016 · 2 investors · BiotechnologyRule 506(b)
▶$10MraisedApr 2016 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Xiaochang DaiDirector
- Yang (Patrick) Lu, PhDExecutive Officer, Director
- Ping LauDirector
- George JiExecutive Officer
- Michael MolyneauxExecutive Officer, Director
- Mike GhiasDirector
- Offering amount
- $10M
- Amount sold
- $10M
- Minimum investment
- $2.5M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 8
by search overlap
Sionnatx43 shared keywordsSionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs. It is advancing a portfolio of NBD1 stabilizers and complementary CFTR modulators intended to be used in combination to normalize CFTR function in CF patients.
Ronatherapeutics38 shared keywordsRona Therapeutics develops siRNA-based therapeutics using its GAIA platform to target metabolic and cardiovascular conditions including hypertriglyceridemia, obesity, ASCVD, and MASH. Its pipeline includes APOC3, INHBE, PCSK9-Lp(a), and angiotensinogen-targeting candidates for patients with cardiovascular and metabolic diseases.
Switch Therapeutics30 shared keywordsSwitch Therapeutics develops RNA interference (RNAi) therapeutic applications targeting central nervous system diseases, leveraging research from Caltech, Harvard Medical School, and City of Hope.
Syrna Therapeutics28 shared keywordsSyrna Therapeutics is a biotech company developing small-molecule covalent translation inhibitors that bind and modify structured domains in the mRNA of disease-causing proteins to block their expression. It uses a 3D structure-guided drug discovery platform, with lead programs in immunology and neurodegeneration and a broader pipeline spanning metabolic disease and oncology.
Siriusrna24 shared keywordsSirius Therapeutics is a biopharmaceutical company developing siRNA-based therapeutics, including work in the anti-coagulant therapeutic area. It focuses on drug discovery and clinical development of RNA-based medicines.
Day One Biopharmaceuticals23 shared keywordsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.
Orna23 shared keywordsOrna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications. The company leverages proprietary drug development expertise in oRNA and LNP technology platforms.
Inspirna21 shared keywordsInspirna is a clinical-stage biopharmaceutical company developing novel cancer drugs that target previously undruggable drivers of metastasis using its proprietary miRNA-DRIVEr platform. The company focuses on common cancers with high unmet need through small molecules and biologics.
Companies competing with Sirnaomics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $221.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $269.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $234.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $250K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2008 | $228K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Sirnaomics do?
- Sirnaomics is an RNA therapeutics company developing RNA interference (RNAi) drugs using its proprietary PNP (Peptide Nanoparticle) delivery platform for extra-hepatic delivery and its GalAHead technology for controlling therapeutic duration. Its pipeline spans oncology, regenerative and aesthetic medicine, and cardiovascular and metabolic diseases.
- Who founded Sirnaomics?
- Sirnaomics was founded by Yang (Patrick) Lu, PhD.
- How much funding has Sirnaomics raised?
- Sirnaomics has disclosed $162M raised across 5 rounds.
- Where is Sirnaomics headquartered?
- Sirnaomics is headquartered in Gaithersburg, US.